Equity · Healthcare
CRBU
NASDAQCaribou Biosciences (CRBU)
The line runs 1.30 USD on 14 September through 0.2954 USD on 20 November, on a scale from 0.0 to 1.5. Days the market did not trade hold the previous close, flat.
- Market cap
- 31.9M USD
- Revenue, year to Dec 2025
- 11.2M USD
- EPS, diluted, year to Dec 2025
- −1.59 USD
- Avg volume
- 129.4K
as of Nov 20, 2026
Have Caribou Biosciences (CRBU) insiders bought or sold shares recently?
CRBU's newest Form 4 filing is dated 25 February 2026: none in the last 90 days.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 25 Feb 2026 | Kelly Timothy PChief Technology Officer | Sell | 6,228 | 12K USD |
| 24 Feb 2026 | Albertson Tina M.Chief Medical Officer | Sell | 1,066 | 2K USD |
| 24 Feb 2026 | MCCLUNG BARBARA GChief Legal Officer | Sell | 6,938 | 14K USD |
| 24 Feb 2026 | Kelly Timothy PChief Technology Officer | Sell | 3,147 | 6K USD |
| 24 Feb 2026 | Khan Ruhi AhmadChief Business Officer | Sell | 6,938 | 14K USD |
| Sold | 5 open-market sales | 24,317 | $47K |
6 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 20 Feb 2026 | Albertson Tina M.Chief Medical Officer | Award | 55,000 | |
| 20 Feb 2026 | MCCLUNG BARBARA GChief Legal Officer | Award | 45,000 | |
| 20 Feb 2026 | Kelly Timothy PChief Technology Officer | Award | 45,000 | |
| 20 Feb 2026 | Khan Ruhi AhmadChief Business Officer | Award | 45,000 | |
| 20 Feb 2026 | Haurwitz Rachel E.President and CEO | Award | 151,700 | |
| 20 Feb 2026 | Ryali SriramChief Financial Officer | Award | 55,000 |
Which funds hold Caribou Biosciences (CRBU)?
7 of the 45 institutional funds we track reported a Caribou Biosciences position for the quarter ended 30 Sep 2026 — a combined 8.3M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Renaissance Technologies | Held (±25%) | 2,556,008 | 3.2M USD | −7.8% |
| AQR Capital Management | New position | 1,632,673 | 2.1M USD | |
| Two Sigma Investments | Trimmed | 674,627 | 857K USD | −35.5% |
| Maverick Capital | Held (±25%) | 652,542 | 829K USD | |
| Marshall Wace | Added | 575,216 | 731K USD | +53.1% |
| Man Group | Added | 327,502 | 416K USD | +36.4% |
| Citadel Advisors | Added | 107,367 | 136K USD | +165.7% |
| Millennium Management | Exited | |||
| Point72 Asset Management | Exited |
What has been filed or recorded for Caribou Biosciences (CRBU)?
The filings we hold for Caribou Biosciences, newest first: 5 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 23 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 23 Oct 2026 | Fails to deliver | Shares failed to deliver | 99,809 shares | 56K USD notional · 0.092% of shares out |
| 19 Oct 2026 | Fails to deliver | Shares failed to deliver | 21 shares | 10 USD notional · <0.001% of shares out |
| 16 Oct 2026 | Fails to deliver | Shares failed to deliver | 149 shares | 69 USD notional · <0.001% of shares out |
| 15 Oct 2026 | Fails to deliver | Shares failed to deliver | 77,671 shares | 36K USD notional · 0.072% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 74,206 shares | 46K USD notional · 0.069% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.25 USD | |
| 30 Sep 2026 | Financials | Total assets | 123.0M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 76.6M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.24 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.26 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.59 USD | |
| 31 Dec 2025 | Financials | Revenue | 11.2M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −148.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.59 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.30 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.58 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.43 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.65 USD |
What do people ask about Caribou Biosciences (CRBU)?
What did Caribou Biosciences shares close at?0.2954
Caribou Biosciences closed at 0.2954 USD on 20 Nov 2026, down 6.04% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Caribou Biosciences’ market cap?31.9M
Caribou Biosciences is worth 31.9M USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Caribou Biosciences’ revenue?11.2M
Caribou Biosciences reported revenue of 11.2M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Caribou Biosciences insiders bought or sold shares recently?
No Caribou Biosciences insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 25 Feb 2026 (SEC Form 4). See Insiders
Which funds own Caribou Biosciences?7 of 45
7 of the 45 funds we track reported a Caribou Biosciences position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, AQR Capital Management and Two Sigma Investments. See Funds
When did Caribou Biosciences last report earnings?−0.25
Caribou Biosciences last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.25 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words